Topoisomerase II-alpha inhibitor

DRUG CLASS:

Topoisomerase II-alpha inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

L-ANN (2)

›

22d

Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases (clinicaltrials.gov)

P1/2, N=36, Completed, Moleculin Biotech, Inc. | Active, not recruiting --> Completed | Phase classification: P1b/2 --> P1/2 | Trial completion date: May 2024 --> Aug 2024

22 days ago

Trial completion • Phase classification • Trial completion date

liposomal annamycin (L-ANN)

2ms

Dual inhibition of topoisomerase II and microtubule of podophyllotoxin derivative 5p overcomes cancer multidrug resistance. (PubMed, Eur J Pharmacol)

In addition, 5p efficiently impaired tumor growth in KB xenograft mice. Conclusively, this work elucidated the dual inhibitor of topoisomerase II and microtubule of 5p and its mechanism of overcoming the multidrug resistance, indicating that 5p exerts the antitumor potentiality.

2 months ago

Journal • PARP Biomarker

ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CASP3 (Caspase 3) • CCNB1 (Cyclin B1) • GSDME (Gasdermin E) • H2AX (H2A.X Variant Histone)

4ms

Effects of Topoisomerase II alpha Inhibition on Oral Cancer Cell Metabolism and Cancer Stem Cell Function. (PubMed, Dent Res Oral Health)

Oral carcinoma cell line SCC25 was cultured in complete DMEM/F12 media and treated with 5μM of Etoposide (Topoisomerase II inhibitor) for 48h...These results indicate that inhibition of TOP2A is more efficacious by decreasing the mitochondrial metabolic reprogramming and thereby downregulating the key anti-apoptotic and pro-survival mediators. Thus, TOP2A represents an ideal therapeutic target and offers a potential treatment strategy for OSCC.

4 months ago

Journal • Cancer stem

TOP2A (DNA topoisomerase 2-alpha) • IL6 (Interleukin 6) • BIRC5 (Baculoviral IAP repeat containing 5) • SOX2 • POU5F1 (POU Class 5 Homeobox 1)

etoposide IV • etoposide oral